Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Lili Du(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Angela DeMichele(University of Pennsylvania), Jodi M. Carter(University of Alberta), Richard B. Schwab(Center for Personalized Cancer Treatment), Sonal Shad(University of California, San Francisco), Lajos Pusztai(Yale University), Marieke van der Noordaa(University of California, San Francisco), Lamorna Brown Swigart(University of California, San Francisco), Tufia C. Haddad(Mayo Clinic), Judy C. Boughey(Mayo Clinic in Arizona), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Martin Klein(Retina Foundation of the Southwest), A. Jo Chien(University of California, San Francisco), Kathy S. Albain(Loyola University Chicago), Christina Yau(Hospital Authority), Rachel M. Layman(The University of Texas MD Anderson Cancer Center), Sara J. Venters(University of California, San Francisco), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Laura J. Esserman(University of California, San Francisco), M.C. Liu(Mayo Clinic), Donald A. Berry(Berry & Associates (United States)), Gillian L. Hirst(University of California, San Francisco), Vicente Valero(The University of Texas MD Anderson Cancer Center), Isabelle Bedrosian(The University of Texas MD Anderson Cancer Center), Gregor Krings(Cleveland Clinic), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Laura van’t Veer(University of California, San Francisco), Rebekah Gould(The University of Texas MD Anderson Cancer Center), Rita Nanda(University of Chicago)
Cited by 46
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k